TELA Bio, Inc. (TELA) Key Metrics

NASDAQ: TELAValuation, returns, debt and efficiency ratios over 9 years.

TELA valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$44.0M
Enterprise value
$84.9M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
0.6
10-yr median 4.5
Price / book
7.3
10-yr median 8.0
EV / EBITDA
—
Dividend yield
—
Beta
1.36

TELA key metrics, 2017–2025

Fiscal year ended December 31, 2025 · U.S. dollars

TELA valuation Price multiples at each fiscal year-end price.

Price / sales−44.5%
0.7
2025 · hover or tap a bar for each year
2019: 9.62020: 10.7 (+11.7%)2021: 6.3 (−41.1%)2022: 4.5 (−28.2%)2023: 2.6 (−42.7%)2024: 1.2 (−52.0%)2025: 0.7 (−44.5%)
20172025
Price / book+189.9%
8.8
2025 · hover or tap a bar for each year
2019: 4.82020: 4.0 (−16.8%)2021: 9.2 (+132.3%)2022: 13.1 (+41.9%)2023: 8.0 (−38.7%)2024: 3.0 (−62.2%)2025: 8.8 (+189.9%)
20172025
Free cash flow yield−2.3 pts
−51.7%
2025 · hover or tap a bar for each year
2019: −19.1%2020: −12.7% (+6.4 pts)2021: −16.8% (−4.1 pts)2022: −22.8% (−6.0 pts)2023: −27.4% (−4.6 pts)2024: −49.4% (−22.0 pts)2025: −51.7% (−2.3 pts)
20172025

TELA valuation history

Fiscal year-endToday9-year median

TELA returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

TELA debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

TELA cash returned to shareholders

DividendsBuybacksFree cash flow

TELA price vs earnings per share

Share price at year-endEPS (right axis)

TELA key metrics

2017–2025
TELA Bio, Inc. key metrics by fiscal year
202520242023202220212020201920182017
Valuation
Market capitalization$55.4M$86.1M$151.4M$187.1M$185.3M$194.5M$147.7M——
Enterprise value$60.2M$76.5M$147.4M$185.3M$172.8M$151.0M$123.4M——
Price / sales0.71.22.64.56.310.79.6——
Price / book8.83.08.013.19.24.04.8——
EV / sales0.81.12.54.55.98.38.0——
Earnings yield−70.1%−43.9%−30.8%−23.7%−18.0%−14.8%−15.2%——
Free cash flow yield−51.7%−49.4%−27.4%−22.8%−16.8%−12.7%−19.1%——
Shareholder yield (dividends + buybacks)0.0%—0.2%0.1%0.0%0.0%0.0%——
Share price at fiscal year-end$1.18$3.02$6.62$11.50$12.80$15.04$12.95——
Per share
Revenue per share$1.71$2.43$2.56$2.55$2.04$1.41$1.35——
Earnings per share−$0.83−$1.33−$2.04−$2.72−$2.30−$2.23−$1.97——
Operating cash flow per share−$0.60−$1.46−$1.79−$2.50−$2.10−$1.89−$2.24——
Free cash flow per share−$0.61−$1.49−$1.81−$2.62−$2.15−$1.90−$2.47——
Cash per share$1.08$1.85$2.04$2.58$3.04$5.75$4.79——
Book value per share$0.13$1.00$0.83$0.88$1.39$3.79$2.71——
Tangible book value per share$0.11$0.94$0.73$0.73$1.23$3.59$2.46——
Capex per share$0.01$0.03$0.03$0.12$0.04$0.01$0.24——
Debt per share$1.19$1.51$1.87$2.47$2.18$2.38$2.65——
Shares outstanding46.9M28.5M22.9M16.3M14.5M12.9M11.4M——
Change in shares outstanding+64.6%+24.7%+40.6%+12.4%+11.9%+13.4%———
Returns & profitability
Return on equity (ROE)−223.4%−159.9%−281.2%−257.5%−96.3%−72.0%———
Return on invested capital (ROIC)−178.0%−159.6%−253.6%−305.1%−354.8%−330.7%———
Return on assets (ROA)−46.0%−45.8%−64.0%−67.9%−44.7%−37.3%−47.1%−98.7%−137.4%
Return on tangible assets−48.5%−44.2%−61.5%−67.8%−55.2%−34.3%−34.5%−87.8%−137.4%
Free cash flow margin−35.7%−61.4%−70.9%−102.9%−105.4%−135.2%−182.7%−259.7%−388.3%
Financial health
Total debt$55.7M$43.1M$42.8M$40.3M$31.5M$30.8M$30.2M$29.7M$6.2M
Cash & short-term investments$50.8M$52.7M$46.7M$42.0M$43.9M$74.4M$54.6M$17.3M$11.3M
Net debt$4.8M−$9.6M−$4.0M−$1.8M−$12.4M−$43.6M−$24.3M$12.5M−$5.1M
Debt / equity8.821.512.262.811.570.630.98——
Debt / assets0.680.490.550.590.500.360.451.090.40
Current ratio4.205.014.235.035.5812.609.582.432.33
Quick ratio3.594.193.454.084.8612.018.901.982.04
Interest coverage-6.4-6.4-8.4-9.6-8.2-7.1-5.3-9.9-3.7
Working capital$57.6M$62.5M$54.8M$50.0M$48.5M$76.6M$57.6M$13.7M$8.2M
Invested capital$11.1M$18.8M$14.9M$12.5M$7.7M$5.5M$6.6M−$125.4M−$113.3M
Tangible asset value$5.0M$26.7M$16.8M$11.8M$17.8M$46.4M$28.1M−$141.1M−$108.2M
Net current asset value$476,000$19.2M$12.6M$8.9M$16.6M$45.8M$27.4M−$141.8M−$109.4M
Graham net-net per share−$0.23$0.27$0.06−$0.04$0.59$3.16$1.93——
Capital allocation
Share buybacks (net)$0—$289,000$157,000$0$0$0$0$0
Capex / revenue0.6%1.4%1.0%4.5%2.1%0.9%17.5%18.9%2.7%
Capex / depreciation0.440.980.761.581.170.324.631.250.15
Stock-based compensation / revenue4.7%6.3%8.6%9.6%12.4%11.3%3.0%2.6%4.6%
R&D / revenue11.5%12.7%16.5%21.6%22.9%23.4%26.9%52.4%136.3%
SG&A / revenue98.3%21.2%127.6%137.9%140.9%177.1%157.2%224.1%322.0%
Efficiency
Days sales outstanding46.552.251.147.842.855.348.845.365.1
Days of inventory on hand167.5207.5248.3246.9198.2222.5264.6210.9386.7
Days payables outstanding31.430.531.950.152.5100.0194.9168.7321.1
Cash conversion cycle (days)182.6229.3267.5244.7188.5177.9118.687.6130.7
Receivables turnover7.856.997.157.638.526.607.478.055.61
Payables turnover11.6411.9611.467.286.953.651.872.161.14
Inventory turnover2.181.761.471.481.841.641.381.730.94
Asset turnover0.950.840.800.640.400.240.320.390.27
Average receivables$10.2M$9.9M$8.2M$5.4M$3.5M$2.8M$2.1M$1.0M$757,000
Average payables$2.2M$1.9M$1.6M$2.0M$1.5M$1.9M$3.3M$2.5M$1.5M
Average inventory$11.9M$13.0M$12.5M$9.7M$5.8M$4.3M$4.5M$3.1M$1.8M
Intangibles / total assets1.7%2.0%2.7%3.7%3.7%3.0%4.3%11.8%0.0%

Computed from TELA's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

TELA valuation and financial ratios

TELA Bio earned a return on equity of −223.4% and a return on invested capital of −178.0% in fiscal 2025. It ended the year with $55.7 million of debt and $50.8 million in cash and short-term investments, net debt of $4.8 million.

See the TELA income statement, the TELA chart for price history, or the TELA stock overview for the latest quote and news.

TELA key metrics FAQ

What is TELA Bio's return on equity?

TELA Bio's return on equity (ROE) was −223.4% in fiscal 2025: net income of -$38.8 million on average shareholders' equity of $17.4 million.

What is TELA Bio's ROIC?

TELA Bio's return on invested capital was −178.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does TELA Bio have?

TELA Bio had total debt of $55.7 million at the end of fiscal 2025, a debt-to-equity ratio of 8.82.

What is TELA Bio's free cash flow yield?

TELA Bio generated -$28.7 million of free cash flow in fiscal 2025, a free cash flow yield of −51.7% on its market value at year-end ($55.4 million).

What is TELA Bio's current ratio?

TELA Bio's current ratio was 4.20 at the end of fiscal 2025: current assets were 4.20 times current liabilities.

Medical Devices key metrics